NCT07247084

A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

A Phase 4 Multicenter, Randomized, Open-Label, Interventional Study With Pragmatic Elements Investigating the Effectiveness of Tirzepatide Once Weekly Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes in a Real-World Setting

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 3,000 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	Tirzepatide	Administered SC
OTHER	Standard of Care	Standard of care

Timeline

• Start date: 2025-11-24
• Primary completion: 2029-07-01
• Completion: 2032-07-01
• First posted: 2025-11-25
• Last updated: 2026-04-17

Locations

30 sites across 1 country: United Kingdom

Regulatory

• FDA-regulated drug study